Birdwatch Note
2025-02-11 02:39:47 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
One new study suggests there may be a connection between semaglutide use and increased risk for a blinding eye disease called non-arteritic anterior ischemic optic neuropathy (NAION). More research is necessary to test the hypothesis. https://www.aao.org/eye-health/news/can-ozempic-affect-eye-health-here-s-what-ophthalm
Written by 869C696B7C07E093829A0B364FF12AA8FA76DCF2C60CB236F9298C34FAE4E35C
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1889109700571992403
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1889142256151433353
- noteId - 1889142256151433353
- participantId -
- noteAuthorParticipantId - 869C696B7C07E093829A0B364FF12AA8FA76DCF2C60CB236F9298C34FAE4E35C Participant Details
- createdAtMillis - 1739241587089
- tweetId - 1889109700571992403
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- One new study suggests there may be a connection between semaglutide use and increased risk for a blinding eye disease called non-arteritic anterior ischemic optic neuropathy (NAION). More research is necessary to test the hypothesis. https://www.aao.org/eye-health/news/can-ozempic-affect-eye-health-here-s-what-ophthalm
Note Ratings
| rated at | rated by | |
| 2025-02-11 23:25:29 -0600 | Rating Details | |
| 2025-02-11 17:57:11 -0600 | Rating Details | |
| 2025-02-11 17:35:59 -0600 | Rating Details | |
| 2025-02-11 13:12:05 -0600 | Rating Details | |
| 2025-02-11 12:13:10 -0600 | Rating Details | |
| 2025-02-11 11:45:03 -0600 | Rating Details | |
| 2025-02-11 10:45:30 -0600 | Rating Details | |
| 2025-02-11 09:58:35 -0600 | Rating Details | |
| 2025-02-11 09:51:50 -0600 | Rating Details | |
| 2025-02-11 09:00:54 -0600 | Rating Details | |
| 2025-02-11 08:45:38 -0600 | Rating Details | |
| 2025-02-11 06:39:41 -0600 | Rating Details | |
| 2025-02-11 05:59:33 -0600 | Rating Details | |
| 2025-02-11 05:33:38 -0600 | Rating Details | |
| 2025-02-11 05:30:03 -0600 | Rating Details | |
| 2025-02-11 05:18:53 -0600 | Rating Details | |
| 2025-02-11 04:58:22 -0600 | Rating Details | |
| 2025-02-11 04:49:49 -0600 | Rating Details | |
| 2025-02-11 04:29:12 -0600 | Rating Details | |
| 2025-02-11 03:29:23 -0600 | Rating Details | |
| 2025-02-11 03:01:50 -0600 | Rating Details | |
| 2025-02-11 02:18:39 -0600 | Rating Details | |
| 2025-02-11 01:11:29 -0600 | Rating Details | |
| 2025-02-10 23:33:50 -0600 | Rating Details | |
| 2025-02-10 23:25:23 -0600 | Rating Details | |
| 2025-02-10 23:02:57 -0600 | Rating Details | |
| 2025-02-10 23:01:53 -0600 | Rating Details | |
| 2025-02-10 22:32:58 -0600 | Rating Details | |
| 2025-02-10 22:31:12 -0600 | Rating Details | |
| 2025-02-10 22:30:52 -0600 | Rating Details | |
| 2025-02-10 22:29:09 -0600 | Rating Details | |
| 2025-02-10 22:21:29 -0600 | Rating Details | |
| 2025-02-10 22:02:46 -0600 | Rating Details | |
| 2025-02-10 21:48:15 -0600 | Rating Details | |
| 2025-02-10 21:46:53 -0600 | Rating Details | |
| 2025-02-10 21:43:26 -0600 | Rating Details | |
| 2025-02-10 21:43:00 -0600 | Rating Details | |
| 2025-02-10 21:42:51 -0600 | Rating Details | |
| 2025-02-10 21:42:13 -0600 | Rating Details | |
| 2025-02-10 21:37:28 -0600 | Rating Details | |
| 2025-02-10 21:28:36 -0600 | Rating Details | |
| 2025-02-10 21:26:27 -0600 | Rating Details | |
| 2025-02-10 21:19:10 -0600 | Rating Details | |
| 2025-02-10 21:18:18 -0600 | Rating Details | |
| 2025-02-10 21:15:13 -0600 | Rating Details | |
| 2025-02-10 21:13:27 -0600 | Rating Details | |
| 2025-02-10 21:10:06 -0600 | Rating Details | |
| 2025-02-10 21:08:06 -0600 | Rating Details | |
| 2025-02-10 21:07:16 -0600 | Rating Details | |
| 2025-02-10 21:02:23 -0600 | Rating Details | |
| 2025-02-10 21:00:10 -0600 | Rating Details | |
| 2025-02-10 20:59:20 -0600 | Rating Details | |
| 2025-02-10 20:55:19 -0600 | Rating Details | |
| 2025-02-10 20:54:31 -0600 | Rating Details | |
| 2025-02-10 20:54:05 -0600 | Rating Details | |
| 2025-02-11 14:38:33 -0600 | Rating Details | |
| 2025-02-11 11:58:45 -0600 | Rating Details | |
| 2025-02-11 09:54:36 -0600 | Rating Details | |
| 2025-02-11 09:13:26 -0600 | Rating Details | |
| 2025-02-11 07:17:37 -0600 | Rating Details | |
| 2025-02-11 07:11:27 -0600 | Rating Details | |
| 2025-02-11 07:11:26 -0600 | Rating Details | |
| 2025-02-11 04:52:44 -0600 | Rating Details | |
| 2025-02-11 03:32:27 -0600 | Rating Details | |
| 2025-02-11 01:42:13 -0600 | Rating Details | |
| 2025-02-11 01:35:26 -0600 | Rating Details | |
| 2025-02-11 01:35:15 -0600 | Rating Details | |
| 2025-02-11 01:01:30 -0600 | Rating Details | |
| 2025-02-10 22:45:38 -0600 | Rating Details | |
| 2025-02-10 22:34:21 -0600 | Rating Details | |
| 2025-02-10 22:29:34 -0600 | Rating Details | |
| 2025-02-10 21:57:45 -0600 | Rating Details | |
| 2025-02-10 21:54:20 -0600 | Rating Details | |
| 2025-02-10 21:27:48 -0600 | Rating Details | |
| 2025-02-10 21:23:53 -0600 | Rating Details | |
| 2025-02-10 21:19:12 -0600 | Rating Details | |
| 2025-02-10 21:19:06 -0600 | Rating Details | |
| 2025-02-10 21:17:25 -0600 | Rating Details | |
| 2025-02-10 21:11:25 -0600 | Rating Details | |
| 2025-02-10 20:58:59 -0600 | Rating Details |